Business Context and Reporting Period
Company: Innate Pharma S.A.
Filing Type: Form 6-K (Report of Foreign Private Issuer)
Reporting Period: Month of May 2021
Date of Report: May 28, 2021
Principal Executive Office: 117 Avenue de Luminy, 13009 Marseille, France
This filing serves to incorporate by reference a press release (Exhibit 99.1) dated May 28, 2021, into the company's registration statement on Form F-3 (File No. 333-252074). The document itself contains no narrative business description or operational details beyond the incorporation reference.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This Form 6-K acts solely as a vehicle to reference an external press release and does not contain a financial table or quantitative data within the provided text.
Material Changes
The filing text does not provide a clear value regarding material changes versus the prior comparable period. No comparative financial data or operational updates are included in the body of this specific document.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for guidance, outlook, management commentary, risks, contingencies, or unusual items. These details are presumed to be contained within the referenced Exhibit 99.1 (Press Release), which is not included in the input text.
Investor Verification Checklist
- Verify the content of Exhibit 99.1 (Press Release dated May 28, 2021) to obtain the specific news or data triggering this filing.
- Review the company's Form F-3 (File No. 333-252074) to understand the context of the incorporation by reference.
- Confirm the identity of the signatory, Laure-Hélène Mercier, as the Chief Financial Officer authorizing the report.
- Check subsequent filings to see if the referenced press release has been superseded by updated information.